FDA approves second PrEP drug to prevent HIV infection

04:07 EDT 4 Oct 2019 | Pharmafile

The US FDA has approved Gilead’s Descovy (emtricitabine/tenofovir alafenamide) as a second pre-exposure prophylaxis (PrEP) drug in at-risk adults and adolescents weighing at least 75lbs for the prevention of HIV infection.

The safety and efficacy of the drug were evaluated in the randomised, double-blind multinational DISCOVER trial in 5387 HIV-negative men and transgender women who have sex with men. The trial compared the once-daily Descovy to Truvada.

read more

Original Article: FDA approves second PrEP drug to prevent HIV infection


More From BioPortfolio on "FDA approves second PrEP drug to prevent HIV infection"

Quick Search

Relevant Topics

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...